DE69531939T2 - Palladium katalysierter ringschluss von triazolyl-tryptamin - Google Patents

Palladium katalysierter ringschluss von triazolyl-tryptamin Download PDF

Info

Publication number
DE69531939T2
DE69531939T2 DE69531939T DE69531939T DE69531939T2 DE 69531939 T2 DE69531939 T2 DE 69531939T2 DE 69531939 T DE69531939 T DE 69531939T DE 69531939 T DE69531939 T DE 69531939T DE 69531939 T2 DE69531939 T2 DE 69531939T2
Authority
DE
Germany
Prior art keywords
compound
formula
palladium
indol
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531939T
Other languages
German (de)
English (en)
Other versions
DE69531939D1 (de
Inventor
Y. Cheng CHEN
D. Robert LARSEN
R. Thomas VERHOEVEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69531939D1 publication Critical patent/DE69531939D1/de
Application granted granted Critical
Publication of DE69531939T2 publication Critical patent/DE69531939T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Inorganic Insulating Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
DE69531939T 1994-05-24 1995-05-19 Palladium katalysierter ringschluss von triazolyl-tryptamin Expired - Lifetime DE69531939T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine
US248288 1994-05-24
PCT/US1995/005506 WO1995032197A1 (en) 1994-05-24 1995-05-19 Palladium catalyzed ring closure of triazolyl tryptamine

Publications (2)

Publication Number Publication Date
DE69531939D1 DE69531939D1 (de) 2003-11-20
DE69531939T2 true DE69531939T2 (de) 2004-07-29

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531939T Expired - Lifetime DE69531939T2 (de) 1994-05-24 1995-05-19 Palladium katalysierter ringschluss von triazolyl-tryptamin

Country Status (24)

Country Link
US (1) US5567824A (https=)
EP (1) EP0763032B1 (https=)
JP (1) JP3947216B2 (https=)
KR (1) KR100385027B1 (https=)
CN (2) CN1077104C (https=)
AT (1) ATE252095T1 (https=)
AU (1) AU688505B2 (https=)
DE (1) DE69531939T2 (https=)
DK (1) DK0763032T3 (https=)
ES (1) ES2207648T3 (https=)
FI (1) FI116899B (https=)
HK (1) HK1041262B (https=)
HR (1) HRP950304B1 (https=)
HU (1) HU226460B1 (https=)
MX (1) MX9605838A (https=)
NZ (1) NZ285539A (https=)
PT (1) PT763032E (https=)
RO (1) RO118586B1 (https=)
RU (1) RU2138496C1 (https=)
SK (1) SK284495B6 (https=)
TW (1) TW300221B (https=)
UA (1) UA52586C2 (https=)
WO (1) WO1995032197A1 (https=)
YU (1) YU49345B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
ATE207485T1 (de) * 1995-07-11 2001-11-15 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
CN1084751C (zh) * 1996-08-13 2002-05-15 麦克公司 钯催化的吲哚化反应
EE04592B1 (et) * 1999-06-28 2006-02-15 Janssen Pharmaceutica N.V. Respiratoorse süntsütiaalviiruse replikatsiooni inhibiitorid, nende valmistamismeetod, kasutamine ja vaheühendid, farmatseutiline kompositsioon ja selle valmistamismeetod ning produkt
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US7777049B2 (en) * 2004-01-09 2010-08-17 Ratiopharm Gmbh Crystalline forms of Rizatriptan benzoate
EP1751104B1 (en) * 2004-01-28 2010-03-24 ratiopharm GmbH Synthesis methods and intermediates for the manufacture of rizatriptan
PA8626701A1 (es) * 2004-03-26 2006-05-16 Wyeth Corp Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
WO2007054979A1 (en) * 2005-11-14 2007-05-18 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
WO2007083320A2 (en) * 2006-01-19 2007-07-26 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
WO2008149152A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
US12194158B2 (en) 2016-01-27 2025-01-14 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
SK149896A3 (en) 1997-09-10
HK1041262A1 (en) 2002-07-05
YU33495A (sh) 1998-07-10
FI964669A0 (fi) 1996-11-22
US5567824A (en) 1996-10-22
FI116899B (fi) 2006-03-31
MX9605838A (es) 1997-12-31
CN1157390C (zh) 2004-07-14
HUT76469A (en) 1997-09-29
HK1009045A1 (en) 1999-05-21
DK0763032T3 (da) 2004-02-09
DE69531939D1 (de) 2003-11-20
NZ285539A (en) 1998-06-26
RO118586B1 (ro) 2003-07-30
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
EP0763032B1 (en) 2003-10-15
ES2207648T3 (es) 2004-06-01
HU9603236D0 (en) 1997-01-28
YU49345B (sh) 2005-07-19
HRP950304A2 (en) 1997-08-31
AU688505B2 (en) 1998-03-12
CN1152920A (zh) 1997-06-25
HU226460B1 (en) 2008-12-29
TW300221B (https=) 1997-03-11
CN1322725A (zh) 2001-11-21
KR970703336A (ko) 1997-07-03
EP0763032A1 (en) 1997-03-19
HRP950304B1 (en) 2004-12-31
CN1077104C (zh) 2002-01-02
JP3947216B2 (ja) 2007-07-18
WO1995032197A1 (en) 1995-11-30
ATE252095T1 (de) 2003-11-15
JPH10500680A (ja) 1998-01-20
SK284495B6 (sk) 2005-05-05
KR100385027B1 (ko) 2003-08-14
HK1041262B (zh) 2005-04-15
PT763032E (pt) 2004-02-27
FI964669L (fi) 1996-11-22
AU2467195A (en) 1995-12-18

Similar Documents

Publication Publication Date Title
DE69531939T2 (de) Palladium katalysierter ringschluss von triazolyl-tryptamin
DE69738457T2 (de) Verfahren zur Herstellung von Oxazolidinonen
DE3241102A1 (de) Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
DE69922009T2 (de) Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren
US4210657A (en) Aryl imidazolyl vinyl ethers and processes for using same
DD146824A5 (de) Verfahren zur herstellung von hydroxypropyl-triazolen
DE3878268T2 (de) Heterocyclische verbindungen.
DE2834322A1 (de) 4-substituierte pyrazole
EP0350437B1 (de) 3,4-Disubstituierte Phenyl-Heterocyclen und deren Verwendung
EP0370300A2 (de) Cyclopropyl-Substituierte Azolylmethylcarbinole, Verfarhren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
Pardo et al. Synthesis of 1-(p-nitrobenzyl) azoles and 1-(p-nitrobenzyl) benzazoles
DE3232737A1 (de) 2-aryl-2-azolylmethyl-1,3-dioxepine
DE60114889T2 (de) Verfahren zur herstellung von fluconazole und kristallmodifikationen davon
CA2190851C (en) Palladium catalyzed ring closure of triazolyl tryptamine
DE69825784T2 (de) Verfahren zur herstellung von triazol derivaten
EP1035127B1 (de) Verfahren zur Herstellung von N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorphenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamid
DE69827042T2 (de) Verfahren zur herstellung von antimykotischen triazol verbindungen
EP0108322B1 (de) Keten-0,0-acetale und Verfahren zu ihrer Herstellung
DE69127396T2 (de) Verfahren zur Herstellung von Dihydrofuranonderivaten
HK1009045B (en) Palladium catalyzed ring closure of triazolyl tryptamine
AT382868B (de) Verfahren zur herstellung neuer azolderivate und deren salze
CH644598A5 (en) Process for the preparation of 1-(triphenylmethyl)imidazoles
EP0110116A2 (de) Verfahren zur Herstellung von Keten-O,N-acetalen
DE10012168A1 (de) Verfahren zur Herstellung von 3.3Dichlor-1,1,1-trifluoraceton
DE3733754A1 (de) Verfahren zur herstellung von 1-(4-chlorphenyl)-3-(1,2,4-triazol-1-yl-methyl)-4,4-dimethyl-pentan-3-ol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 763032

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 763032

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213